In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...
This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...
RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in pediatric ICU utilization.
New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...
RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.
Cases of respiratory syncytial virus, or RSV, are widespread across the area – even as providers at Pediatric Care Specialists continue seeing young patients for a continued trend of "walking ...
Researchers report that immunity against pertussis (whooping cough) was sustained 5 years after receipt of a recombinant ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
Now that colder temperatures have arrived, the Illinois Department of Public Health (IDPH) is reminding Illinoisans to ...
Coughing, sneezing, wheezing? High fever and no sleep? Your child may have RSV.
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.